
During fetal development, the foramen ovale is an important component of normal fetal circulation, allowing oxygenated blood to bypass the nonfunctional fetal lungs and supporting fetal growth and development. After birth, incomplete fusion of the septum primum and septum secundum may result in a persistent patent foramen ovale (PFO), which is present in approximately 25% of adults. Although most individuals remain asymptomatic, PFO has been recognized as an important contributor to paradoxical embolism and cryptogenic ischemic stroke. The clinical significance of PFO depends not only on its presence, but also on patient characteristics and anatomical features that influence the likelihood of right-to-left shunting and embolic events. High-risk morphology characteristics, including a large interatrial communication, elongated tunnel length, and prominent Eustachian valve or Chiari network, are associated with increased embolic potential. Advances in multimodality imaging, particularly contrast transesophageal echocardiography, have improved the diagnosis and anatomical characterization of PFO, while risk stratification tools such as the Risk of Paradoxical Embolism (RoPE) score and the PASCAL classification are important tools when determining whether a PFO is likely to be causally related to ischemic stroke. Treatment options for PFO are also largely related to the risk and morphology of the PFO, with age and risk of recurrent strokes impacting potential treatment options. Closure of PFO may not be recommended in all patients; however, percutaneous closure has become more prevalent in recent years due to its less invasive nature.
Coronary artery disease commonly coexists with severe aortic stenosis in transcatheter aortic valve implantation (TAVI) candidates, yet optimal revascularization remains debated. We meta-analyzed randomized controlled trials comparing routine percutaneous coronary intervention (PCI) before or concomitant with TAVI versus conservative management. Major databases were searched through May 2026. Random-effects models calculated risk ratios (RRs) with 95% confidence intervals (CIs), and evidence certainty was evaluated via the Grading of Recommendations Assessment, Development and Evaluation. Three randomized controlled trials (1156 patients; PCI: n = 579, conservative: n = 577) were included. Routine PCI was not associated with significant reductions in all-cause mortality (RR, 0.90; 95% CI, 0.70-1.15; P = 0.40), cardiac death (RR, 0.74; 95% CI, 0.51-1.08; P = 0.12), myocardial infarction (RR, 0.86; 95% CI, 0.45-1.64; P = 0.64), stroke (RR, 0.70; 95% CI, 0.48-1.03; P = 0.07), or hospitalization (RR, 1.07; 95% CI, 0.87-1.32; P = 0.52). However, PCI significantly increased major bleeding (RR, 1.57; 95% CI, 1.06-2.34; P = 0.02) and any bleeding (RR, 1.77; 95% CI, 1.27-2.48; P = 0.0008), while reducing urgent and repeat revascularization. In conclusion, routine PCI before or concomitant with TAVI reduces subsequent revascularization without conferring survival or ischemic benefit, while increasing bleeding complications. Given the moderate-to-low certainty of evidence, limited cumulative sample size, and clinical heterogeneity across trials, these findings warrant cautious interpretation and favor an individualized, Heart Team-guided revascularization strategy over routine PCI.
Congenital heart block (CHB) is a rare but potentially life-threatening form of conduction disease that manifests in utero or shortly after birth, resulting from disruption of the normal electrical conduction pathway between the atria and ventricles. The severity of CHB varies depending on the degree of atrioventricular conduction impairment, ranging from first-degree atrioventricular block, characterized by prolonged conduction, to complete third-degree block, in which atrial and ventricular activity are entirely dissociated and function independently. The most common etiology is passive transplacental transfer of maternal anti-Ro/SSA and anti-La/SSB autoantibodies, most frequently in the setting of maternal systemic lupus erythematosus or Sjögren syndrome, even when the mother is clinically asymptomatic. Less commonly, CHB arises in association with structural congenital heart disease, most notably left atrial isomerism and corrected transposition of the great arteries. The clinical spectrum ranges from an incidental prenatal finding to fetal hydrops and in utero death, with third-degree CHB carrying a perinatal mortality rate of approximately 15-30%. This review integrates current evidence on the pathophysiology, maternal autoimmune contributions, diagnostic approach, and management strategies for CHB, with an emphasis on the emerging roles of fetal surveillance, pharmacologic interventions, and postnatal pacing.
Advances in cardiovascular prevention and treatment have substantially improved patient outcomes. However, residual cardiovascular risk remains a major clinical challenge. Traditional lipid-lowering and antihypertensive therapies, although effective, remain limited by suboptimal adherence, adverse effects, and persistent residual cardiovascular risk. RNA-targeted therapeutics have emerged as a transformative therapeutic paradigm, offering durable and highly specific gene silencing through small interfering RNA and antisense oligonucleotide platforms. This review evaluates the current evidence on RNA-targeted therapeutics for cardiovascular risk reduction, with an emphasis on their mechanisms of action, clinical efficacy, safety, and emerging therapeutic applications. A review was conducted using PubMed, Embase, Scopus, ScienceDirect, the Cochrane Library, and ClinicalTrials.gov from inception to June 2026. A total of 154 eligible studies were included and narratively synthesized by therapeutic class and molecular target. Inclisiran reduced low-density lipoprotein cholesterol by approximately 50% with twice-yearly dosing, while pooled ORION analyses suggested a reduction in major adverse cardiovascular events. Pelacarsen, olpasiran, and lepodisiran achieved 80–98% reductions in lipoprotein(a), whereas zilebesiran lowered systolic blood pressure by more than 15 mm Hg with sustained effects for up to 24 weeks. Across studies, RNA therapeutics demonstrated favorable safety profiles, with predominantly mild injection-site reactions. Although definitive cardiovascular outcome data remain unavailable for several emerging agents, RNA-targeted therapeutics represent a promising advance in precision cardiovascular medicine by providing durable, mechanism-based therapies capable of addressing important residual cardiovascular risk.
Approximately 50% of heart failure (HF) patients are malnourished, doubling mortality risk; however, interventional evidence remains limited. A previously published meta-analysis found modest weight improvements only in malnourished/cachectic patients (5 studies, n = 275). This review updates the evidence in a broader HF population to evaluate the effect of nutritional interventions on all-cause mortality, hospital readmissions, and body mass index (BMI) in HF, determine whether intervention type moderates effect size, and identify sources of heterogeneity via meta-regression. This PRISMA-compliant, PROSPERO-registered (CRD420261445761) systematic review and meta-analysis searched PubMed, Scopus, Cochrane, and Embase for randomized controlled trials, quasi-randomized, and observational studies evaluating nutritional interventions (supplements, fortification, enteral/parenteral nutrition, counseling, with or without exercise) to increase protein/energy intake in HF, updating a 2021 search. Two reviewers independently screened, extracted data, and assessed risk of bias (RoB 2.0 for randomized controlled trials; ROBINS-I for observational studies). Random-effects models pooled risk ratios (RRs) and mean differences (MDs), with subgroup, meta-regression, and sensitivity analyses. Of 7190 records screened, 23 studies (n = 2240) were included; 18 contributed to meta-analysis. Risk of bias was predominantly low. Nutritional intervention significantly reduced all-cause mortality (RR 0.43, 95% confidence interval: 0.26–0.71, P = 0.001), with no significant effect on readmission or BMI. Exercise capacity improved significantly (6-minute walk distance mean difference 25.01, 95% confidence interval: 5.26–44.76, P = 0.013), while quality of life, creatinine, and B-type natriuretic peptide showed no significant change. Nutritional intervention was associated with reduced mortality and improved exercise capacity in HF, though effects on hospitalization, BMI, and biomarkers were nonsignificant, warranting cautious interpretation.